4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazole-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazole-2-carboxamide
• 英文别名: 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazole-2-carboxamide
• 化学式: C₁₄H₁₄F₃N₃OS
• 分子量: 329.34
• InChiKey: CFDLWESPXGNZQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  97.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K
  申请人：Novartis AG

  公开号：EP2875050A1

  公开（公告）日：2015-05-27
• [EN] COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K<br/>[FR] POLYTHÉRAPIE À BASE D'INHIBITEURS D'IGF1 R ET DE LA PI3K
  申请人：NOVARTIS PHARMA AG

  公开号：WO2014015280A1

  公开（公告）日：2014-01-23

  The present invention relates to a pharmaceutical combination comprising an alpha- isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine- 1,2-dicarboxylic acid 2-amide l-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin- 4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.